IVD Medical Holding Limited (HK:1931)
:1931
Want to see HK:1931 full AI Analyst Report?
Top Page
IVD Medical Holding Limited
(1931)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.79
▼(-79.56% Downside)
Action:Reiterated
Date:05/11/26
The score is held down primarily by the sharp 2025 fundamental deterioration—steep margin compression, a shift to higher leverage, and especially the swing to large negative operating/free cash flow. Technicals add pressure with a clear downtrend (price below all key moving averages) despite oversold readings. Valuation is only mildly supportive because a negative P/E reflects weak earnings and dividend support is not available in the provided data.
Positive Factors
Historic operating margin strength
A multi-year track record of healthy operating margins and positive growth through 2021–2024 indicates underlying operational competence and profitable unit economics. That prior performance supports the view management and the business model can reinstate margins as market conditions normalize.
Negative Factors
Severe cash flow deterioration
Large negative operating and free cash flows materially weaken liquidity and raise near‑term funding risk. Sustained cash outflows limit the company’s ability to fund working capital, invest in growth, or pay down debt, increasing the probability of needing external financing or asset disposals.
Read all positive and negative factors
Positive Factors
Negative Factors
Historic operating margin strength
A multi-year track record of healthy operating margins and positive growth through 2021–2024 indicates underlying operational competence and profitable unit economics. That prior performance supports the view management and the business model can reinstate margins as market conditions normalize.
Read all positive factors
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.30B
Dividend Yield3.81%
Average Volume (3M)1.48M
Price to Earnings (P/E)109.2
Beta (1Y)0.61
Revenue Growth-10.71%
EPS Growth-87.93%
CountryHK
Employees863
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,621,488,000
10 Day Avg. Volume1,443,300
30 Day Avg. Volume1,483,483
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.29
Price to Sales (P/S)1.35
P/FCF Ratio-3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IVD Medical Holding Limited Business Overview & Revenue Model
Company Description
IVD Medical Holding Limited, an investment holding company, distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, Maintenance Services, and Self-br...
How the Company Makes Money
null...
IVD Medical Holding Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.82B | 3.16B | 3.09B | 2.75B | 2.73B |
| Gross Profit | 566.37M | 751.17M | 671.70M | 608.14M | 566.27M |
| EBITDA | 207.28M | 475.96M | 397.93M | 349.66M | 286.17M |
| Net Income | 34.93M | 260.42M | 238.16M | 210.00M | 174.54M |
Balance Sheet | |||||
| Total Assets | 5.94B | 5.52B | 4.79B | 4.31B | 4.37B |
| Cash, Cash Equivalents and Short-Term Investments | 551.05M | 1.86B | 1.24B | 1.04B | 841.78M |
| Total Debt | 1.93B | 755.97M | 344.32M | 349.92M | 427.65M |
| Total Liabilities | 2.93B | 1.76B | 1.40B | 1.16B | 1.37B |
| Stockholders Equity | 2.95B | 3.71B | 3.34B | 3.15B | 2.98B |
Cash Flow | |||||
| Free Cash Flow | -1.01B | 88.69M | 251.92M | 215.39M | 137.88M |
| Operating Cash Flow | -918.89M | 140.29M | 292.42M | 249.67M | 163.11M |
| Investing Cash Flow | -1.35B | -57.80M | -77.58M | 60.54M | -27.88M |
| Financing Cash Flow | 831.04M | 395.13M | -19.45M | -191.29M | -66.29M |
IVD Medical Holding Limited Technical Analysis
Negative
3.85
Price Trends
1.04
Negative
1.40
Negative
4.62
Negative
Market Momentum
-0.06
Negative
30.12
Neutral
16.03
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1931, the sentiment is Negative. The current price of 3.85 is above the 20-day moving average (MA) of 0.90, above the 50-day MA of 1.04, and below the 200-day MA of 4.62, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 30.12 is Neutral, neither overbought nor oversold. The STOCH value of 16.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1931.
IVD Medical Holding Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$5.80B | 19.20 | 6.83% | 2.72% | 15.04% | 5.57% | |
60 Neutral | HK$63.78B | 6.70 | 7.64% | 2.67% | 6.45% | 35.60% | |
60 Neutral | HK$628.56M | 15.28 | 7.59% | 8.03% | -1.01% | -13.09% | |
57 Neutral | HK$54.67B | 7.62 | 8.70% | 3.75% | -1.57% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$456.84M | -0.59 | -66.54% | ― | -53.49% | -68.66% | |
42 Neutral | HK$1.30B | 109.16 | 1.09% | 3.81% | -10.71% | -87.93% |
* Healthcare Sector Average
HK:1931
IVD Medical Holding Limited
0.82
-1.17
-58.79%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.73
0.75
6.83%
HK:1099
Sinopharm Group Co
17.55
-0.24
-1.33%
HK:9955
ClouDr Group Limited
0.72
-0.32
-30.77%
HK:2192
Medlive Technology Co., Ltd.
7.82
-3.90
-33.30%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.82
-1.39
-19.28%
IVD Medical Holding Limited Corporate Events
ETHK Labs Calls 2026 AGM, Seeks Share Buyback Mandate and Director Re-elections
May 22, 2026
ETHK Labs Inc. has called its annual general meeting for 30 June 2026 in Hong Kong, where shareholders will review and approve the audited consolidated financial statements and the directors’ and auditors’ reports for the year ended 31...
ETHK Labs Delays Key Circular on Major Share Acquisition and Voting Rights Deal
Apr 17, 2026
ETHK Labs Inc. has announced a delay in sending to shareholders a circular related to a major transaction involving the acquisition of shares in a target company and associated voting rights entrustment arrangements. The circular, which will inclu...
ETHK Labs Profit Slumps 86% as Competition and Expansion Costs Bite
Mar 27, 2026
ETHK Labs Inc. reported a challenging 2025, with revenue falling 10.8% year-on-year to RMB2.82 billion and gross profit dropping 24.6%, reflecting intensifying competition in the IVD market. Net profit declined sharply by 85.9% to RMB37.4 million,...
ETHK Labs Warns of Sharp 2025 Profit Drop Amid Margin Squeeze and Listing Costs
Mar 11, 2026
ETHK Labs Inc., a Hong Kong-listed in vitro diagnostics company incorporated in the Cayman Islands, develops and sells IVD products in an increasingly competitive market. The Group is also working toward a proposed dual listing in the United State...
ETHK Labs Reclassifies B-Soft Deal as Major Transaction After Listing Rules Review
Mar 11, 2026
ETHK Labs Inc. has clarified that its previously announced acquisition of shares and voting rights in Chinese technology company B-Soft should be treated as a major transaction under Hong Kong listing rules, rather than a discloseable transaction....
ETHK Labs Sets March 2026 Board Meeting to Approve 2025 Results
Mar 11, 2026
ETHK Labs Inc. has scheduled a board meeting for 27 March 2026 to review and approve the group’s audited annual results for the financial year ended 31 December 2025. The board will also consider the declaration of a final dividend, if any, ...
ETHK Labs Clarifies Regulatory Status and Market Path for Nipah Virus Detection Platforms
Mar 4, 2026
ETHK Labs Inc. has provided a detailed update on the regulatory status and business progress of its dual-platform solution for Nipah virus detection, developed via subsidiary Shenzhen ICXIVD Biotechnology. The solution consists of an intelligent f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.